SA PRO
Free Account
Themes
AbbVie Inc.ABBVNYSE
Loading
OverviewIntelligenceChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 72% recommend buying.

Consensus Rating
Buy
25 analysts·High coverage
72%
Rating Distribution
Strong Buy
00%
Buy
1872%
Hold
728%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

2026E$14.56(18 analysts)
P/E99x
Current: 98.7x
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+8.11%
EPS+11.16%
FY2028
Rev+7.33%
EPS+10.28%
FY2029
Rev+5.52%
EPS+9.43%

Earnings Surprises

Recent Analyst Actions

Feb 24, 2026RBC Capital
RBC Capital Starts Abbvie (ABBV) at Outperform
Target:$260.00
+13.8%from $228.44
Feb 19, 2026Barclays
AbbVie initiated with an Overweight at Barclays
Target:$275.00
+22.6%from $224.35
Feb 18, 2026Piper Sandler
AbbVie price target raised to $299 from $289 at Piper Sandler
Target:$299.00
+28.4%from $232.86
Feb 5, 2026UBS
AbbVie price target lowered to $230 from $240 at UBS
Target:$230.00
+5.8%from $217.41
Feb 4, 2026Evercore ISI
AbbVie price target lowered to $228 from $232 at Evercore ISI
Target:$228.00
+5.1%from $217.02
Jan 28, 2026Goldman Sachs
Goldman Sachs Reiterates Neutral Rating on Abbvie (ABBV) Ahead of Earnings
Target:$223.00
+1.5%from $219.77
Jan 20, 2026Berenberg Bank
AbbVie price target raised to $275 from $270 at Berenberg
Target:$275.00
+28.3%from $214.35
Jan 15, 2026BMO Capital
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV)
Target:$258.00
+18.5%from $217.74
Jan 7, 2026UBS
AbbVie assumed with a Neutral at UBS
Target:$240.00
+7.2%from $223.93
Dec 12, 2025Morgan Stanley
AbbVie price target raised to $269 from $261 at Morgan Stanley
Target:$269.00
+20.9%from $222.48
Dec 10, 2025HSBC
AbbVie upgraded to Buy from Hold at HSBC
Target:$265.00
+18.8%from $222.99
Nov 5, 2025Piper Sandler
AbbVie price target raised to $289 from $284 at Piper Sandler
Target:$289.00
+35.3%from $213.57
Nov 3, 2025Raymond James
Abbvie (ABBV) PT Raised to $256 at Raymond James
Target:$256.00
+17.4%from $218.04
Oct 20, 2025Guggenheim
AbbVie price target raised to $242 from $227 at Guggenheim
Target:$242.00
+5.4%from $229.57
Oct 17, 2025Raymond James
AbbVie price target raised to $250 from $236 at Raymond James
Target:$250.00
+10.2%from $226.87
Oct 10, 2025Piper Sandler
AbbVie price target raised to $284 from $231 at Piper Sandler
Target:$284.00
+23.1%from $230.69
Oct 9, 2025Cantor Fitzgerald
AbbVie price target raised to $250 from $245 at Cantor Fitzgerald
Target:$250.00
+8.1%from $231.24
Oct 3, 2025UBS
AbbVie price target raised to $251 from $220 at BofA
Target:$251.00
+6.1%from $236.56
Oct 2, 2025HSBC
AbbVie downgraded to Hold from Buy at HSBC (yesterday)
Target:$225.00
-7.9%from $244.38
Sep 15, 2025Cantor Fitzgerald
AbbVie price target raised to $245 from $215 at Cantor Fitzgerald
Target:$245.00
+12.2%from $218.34
Feb 3, 2025Raymond James
AbbVie price target raised to $220 from $218 at Raymond James
Target:$220.00
+15.7%from $190.14
Feb 3, 2025BMO Capital
AbbVie price target raised to $215 from $208 at BMO Capital
Target:$215.00
+13.1%from $190.14
Nov 12, 2024BMO Capital
Abbvie (ABBV) PT Lowered to $208 at BMO Capital
Target:$208.00
+3.2%from $201.61
Oct 31, 2024BMO Capital
Abbvie (ABBV) PT Raised to $228 at BMO Capital
Target:$228.00
+13.2%from $201.50
Oct 31, 2024Bank of America Securities
AbbVie price target raised to $210 from $195 at BofA
Target:$210.00
+4.2%from $201.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance